Prescription Strategies of Amikacin in Intensive Care Patients on Renal Replacement Therapy: an Observational Prospective Multicenter Study
NCT ID: NCT04322019
Last Updated: 2022-06-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
112 participants
OBSERVATIONAL
2020-05-25
2022-05-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Acute Kidney Injury in Septic Critically Ill Patients : Are Aminoglycosides Really Harmful?
NCT01932814
Antimicrobial Pharmacokinetics in Critically Ill Adults During Sustained Low Efficiency Dialysis (SLED)
NCT02242006
Outcomes of Critically Ill Patients With Severe Acute Kidney Injury Requiring Renal Replacement Therapy
NCT02897310
Artificial Kidney Initiation in Kidney Injury
NCT01932190
2012_PharmacoCRRT-study:Pharmacokinetics of Anti-infectives in Critically Ill Patients in Need of Continuous Renal Replacement Therapy (CRRT)
NCT01582360
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
"Amikacin treatment" group
Intensive care patients on renal replacement therapy with Amikacin treatment
Data record
Data record
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Data record
Data record
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients on extrarenal replacement
* patients with Amikacin treatment
* patients accepting to participate in the study
Exclusion Criteria
* pregnant women
* patients with Amikacin treatment in the previous 7 days
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CHU de Reims
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Damien JOLLY
Reims, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PO20032
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.